Health Dictionary Find a Doctor

Hypocalcemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]Vindhya BellamKonda, M.B.B.S [3]

Synonyms and keywords: hypocalcemia; low serum calcium level; hypocalcaemia

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]Vindhya BellamKonda, M.B.B.S [3]

Overview

Hypocalcemia is the presence of low serum calcium levels in the blood, usually taken as less than 3.5 mmol/L or 8.8 mg/dl or an ionized calcium level of less than 1.1 mmol/L (4.5 mg/dL). It is a type of electrolyte disturbance. In the blood, about half of all calcium is bound to proteins such as serum albumin, but it is the unbound, or ionized, calcium that the body regulates. If a person has abnormal levels of blood proteins then the plasma calcium may be inaccurate. The ionized calcium level is considered more clinically accurate in this case.

Calcium is the most abundant mineral in the body. 99% of the body’s calcium is stored in bone. Calcium is found in plasma and is either protein-bound or ionized and readily available.

Historical Perspective

The association between thyroid and parathyroid surgery and hypocalcemia was made by Billroth, Kocher, Mayo, and Halsted.

Classification

There is a functional classification of hypocalcemia which includes complete absent of PTH gland, PTH insufficiency, and PTH overactivity.

Pathophysiology

Hypocalcemia may develop in disorders associated with insufficient parathyroid hormone or vitamin D production or resistance to hormonal activities. Perturbations of calcium homeostasis can be caused by environmental factors or occur as a result of genetic mutations in the calcium-sensing receptor (as in type 1 autosomal dominant hypocalcemia), Gs α subunit (as in type 1A and 1B pseudohypoparathyroidism), vitamin D hydroxylase (as in type 1 vitamin D-dependent rickets , and calcitriol receptor (as in type 2 vitamin D-dependent rickets).

Causes

Hypocalcemia can be the consequence of multiple disease processes, some of which will be mentioned in the following discussion. Common causes of hypocalcemia include Vitamin D insufficiency, hypoparathyroidism, renal disease, pseudohypoparathyroidism, hypomagnesemia, drugs and fanconi syndrome etc.

Differentiating Hypocalcemia from Other Diseases

Hypocalcemia must be differentiated from tetanus, Neuroleptic Malignant Syndrome, Viral Meningitis, Stiff man syndrome, Strychnine poisoning and Parkinson’s disease.

Epidemiology and Demographics

Hypocalcaemia, is having a low calcium concentrations in the blood.The normal range of serum calcium lies between 8.8–10.7 mg/dl, 4.3–5.2 mEq/l.In the past 20 years quantification of serum and ionized calcium and PTH concentrations, helps in easier diagnosis. It is difficult to quantify the incidence of ionized hypocalcemia.

Risk Factors

The most common risk factors of hypocalcemia are vitamin D deficiency. Other common causes of hypocalcemia include magnesium, newborn babies, parathyroid hormone (PTH), hyperphosphatemia and renal causes.

Screening

There is insufficient evidence to recommend routine screening for hypocalcemia.

Natural History, Complications, and Prognosis

The clinical features of hypocalcemia may vary widely, which ranges from asymptomatic symptoms to life-threatening complications.The main factors that influence the serum calcium levels are parathyroid hormone (PTH), vitamin D, the calcium ions, and phosphate.Hypocalcemia is commonly encountered in patients who are hospitalized. Undertreatment or improper treatment of hypocalcemic emergencies can lead to significant morbidity.Death is rare but has been reported in hypocalcemia patients.

Diagnosis

Diagnostic Criteria

History and Symptoms

Clinical presentation of hypocalcemia reflects the serum level of ionized calcium and depends on the severity of any concurrent electrolyte imbalance. Overt symptoms occur when ionized calcium falls below 3.2 mg/dL (0.8 mmol/L).An abrupt fall in the serum calcium level typically manifests as neuromuscular excitability in the form of tetany and tingling. Patients who develop hypocalcemia gradually may be asymptomatic.In addition to fatigue and muscle weakness, longstanding hypocalcemia is usually associated with neuropsychiatric symptoms.

Physical Examination

The clinical manifestations of hypocalcemia depend on the degree of hypocalcemia. Common physical examination findings of hypocalcemia include Chvostek’s sign, Trousseau’s sign, and circumoral numbness.

Laboratory Findings

Measurement of the serum albumin concentration is essential to distinguish pseudohypocalcemia from true hypocalcemia. Laboratory investigations that detect alterations in parathyroid hormonevitamin D, and phosphate in the serum or urine aid in the differential diagnosis of the underlying etiologies. Other laboratory tests include serum alkaline phosphataseliver function testscoagulation profileblood urea nitrogencreatinine, and urinary cAMP levels at baseline or after PTH challenge.

Imaging Findings

An x-ray may be helpful in the diagnosis of hypocalcemia. Findings on an x-ray suggestive of hypocalcemia include trabeculation and femoral changes.Head CT scan may be helpful in the diagnosis of hypocalcemia. Findings on CT scan suggestive hypocalcemia include basal ganglia calcification.There are no MRI findings associated with hypocalcemia.

Other Diagnostic Studies

There are no other imaging findings associated with hypocalcemia.

Treatment

Medical Therapy

Cause, severity and the presence of symptoms decide the treatment of hypocalcemia. In mild to moderate cases hypocalcemia can be treated by giving oral calcium and vitamin D supplements but in severe cases intravenous (IV) calcium gluconate is preferred. Most of the hypocalcemic cases are mild and require only supportive treatment and laboratory evaluation

Surgery

Surgical intervention is not recommended for the management of hypocalcemia.

Primary Prevention

Effective measures for the primary prevention of hypocalcemia include the increase in dietary calcium and increase exposure to the sun.

Secondary Prevention

There are no established measures for the secondary prevention of hypocalcemia.

References

Template:WH Template:WS

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]Vindhya BellamKonda, M.B.B.S [3]

Overview

The association between thyroid and parathyroid surgery and hypocalcemia was made by Billroth, Kocher, Mayo, and Halsted.

Historical Perspective

Discovery

References

  1. Rogers-Stevane, Jennifer; Kauffman, Gordon L. (2008). “A Historical Perspective on Surgery of the Thyroid and Parathyroid Glands”. Otolaryngologic Clinics of North America. 41 (6): 1059–1067. doi:10.1016/j.otc.2008.08.003. ISSN 0030-6665.

Template:WS Template:WH

Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]Vindhya BellamKonda, M.B.B.S [3]

Overview

Hypocalcemia may be classified functionally into complete absence of parathyroid gland, parathyroid hormone (PTH) insufficiency and PTH overactivity.

Classification

  • Hypocalcemia may be classified functionally into the following sub-types:

Absence of parathyroid gland

PTH insufficiency

PTH overactivity

References

  1. Riccardi D, Brown EM (March 2010). “Physiology and pathophysiology of the calcium-sensing receptor in the kidney”. Am. J. Physiol. Renal Physiol. 298 (3): F485–99. doi:10.1152/ajprenal.00608.2009. PMC 2838589. PMID 19923405.
  2. Sarkar S, Mondal M, Das K, Shrimal A (September 2012). “Mucocutaneous manifestations of acquired hypoparathyroidism: An observational study”. Indian J Endocrinol Metab. 16 (5): 819–20. doi:10.4103/2230-8210.100637. PMC 3475912. PMID 23087872.
  3. Sturniolo G, Lo Schiavo MG, Tonante A, D’Alia C, Bonanno L (2000). “Hypocalcemia and hypoparathyroidism after total thyroidectomy: a clinical biological study and surgical considerations”. Int. J. Surg. Investig. 2 (2): 99–105. PMID 12678507.
  4. Pattou F, Combemale F, Fabre S, Carnaille B, Decoulx M, Wemeau JL, Racadot A, Proye C (July 1998). “Hypocalcemia following thyroid surgery: incidence and prediction of outcome”. World J Surg. 22 (7): 718–24. PMID 9606288.
  5. Sciumè C, Geraci G, Pisello F, Facella T, Li Volsi F, Licata A, Modica G (2006). “[Complications in thyroid surgery: symptomatic post-operative hypoparathyroidism incidence, surgical technique, and treatment]”. Ann Ital Chir (in Italian). 77 (2): 115–22. PMID 17147083.
  6. Carroll R, Matfin G (February 2010). “Endocrine and metabolic emergencies: hypocalcaemia”. Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  7. Zaloga GP, Chernow B (July 1987). “The multifactorial basis for hypocalcemia during sepsis. Studies of the parathyroid hormone-vitamin D axis”. Ann. Intern. Med. 107 (1): 36–41. PMID 3592447.
  8. Carroll R, Matfin G (February 2010). “Endocrine and metabolic emergencies: hypocalcaemia”. Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  9. Brunelli, S. M.; Goldfarb, S. (2007). “Hypophosphatemia: Clinical Consequences and Management”. Journal of the American Society of Nephrology. 18 (7): 1999–2003. doi:10.1681/ASN.2007020143. ISSN 1046-6673.

Template:WS Template:WH

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

Hypocalcemia may develop in disorders associated with insufficient parathyroid hormone or vitamin D production or resistance to hormonal activities. Perturbations of calcium homeostasis can be caused by environmental factors or occur as a result of genetic mutations in the calcium-sensing receptor (as in type 1 autosomal dominant hypocalcemia), Gs α subunit (as in type 1A and 1B pseudohypoparathyroidism), vitamin D hydroxylase (as in type 1 vitamin D-dependent rickets , and calcitriol receptor (as in type 2 vitamin D-dependent rickets).

Pathophysiology

Physiology

The normal physiology of Hypocalcemia can be understood as follows:[1][2]

  • The normal concentrations of calcium in the body is maintained within the narrow range and that is required for the optimal activity of the many extra- and intracellular processes that calcium regulates. 
  • Calcium transport within the blood is mainly via bound to plasma proteins such as albumin (45%), phosphate and citrate (15%) and ionized state (40%).
  • Only the ionized form of calcium is active but most laboratories show report of total serum calcium concentrations.
  • The normal concentration of calcium ranges between 8.5 and 10.5 mg/dL.
  • The normal range of ionized calcium in the plasma is 4.65 to 5.25 mg/dL.

Pathogenesis

It is understood that hypocalcemia may result through any of the following mechanisms:

Vitamin D deficiency

Hypoalbuminemia

  • When there is a fluctuation in serum protein concentrations, especially albumin, total calcium levels in the blood may change.[5][6]
  • Whereas the levels of ionized calcium (free form) remains mostly constant, because it is hormonally regulated.
  • In cases of hypoalbuminemia, total serum calcium levels may not accurately reflect the physiologically important ionized calcium concentration.
  • Therefore, a correction may be required in order to arrive at the corrected calcium levels. (Corrected calcium = Measured calcium + 0.02 x [40 – Albumin])

Hormonal regulation 

Magnesium 

Acid-base disturbances

Alkalosis

  • For an increase in pH of 0.1 unit, there is an approximately 0.05 mmol/L (0.1 mEq/L) fall in the serum level of ionized calcium.

Respiratory alkalosis

Globulin binding

Autoimmune 

Genetics

The development of hypocalcemia is the result of genetic mutations such as

References

  1. Fong J, Khan A (February 2012). “Hypocalcemia: updates in diagnosis and management for primary care”. Can Fam Physician. 58 (2): 158–62. PMC 3279267. PMID 22439169.
  2. Carroll R, Matfin G (February 2010). “Endocrine and metabolic emergencies: hypocalcaemia”. Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  3. Carroll R, Matfin G (February 2010). “Endocrine and metabolic emergencies: hypocalcaemia”. Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  4. Papapoulos SE, Harinck HI, Bijvoet OL, Gleed JH, Fraher LJ, O’Riordan JL (February 1986). “Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD”. Bone Miner. 1 (1): 69–78. PMID 3508718.
  5. Fong J, Khan A (February 2012). “Hypocalcemia: updates in diagnosis and management for primary care”. Can Fam Physician. 58 (2): 158–62. PMC 3279267. PMID 22439169.
  6. Carroll R, Matfin G (February 2010). “Endocrine and metabolic emergencies: hypocalcaemia”. Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  7. Riccardi D, Brown EM (March 2010). “Physiology and pathophysiology of the calcium-sensing receptor in the kidney”. Am. J. Physiol. Renal Physiol. 298 (3): F485–99. doi:10.1152/ajprenal.00608.2009. PMC 2838589. PMID 19923405.
  8. Goodman WG (January 2004). “Calcium-sensing receptors”. Semin. Nephrol. 24 (1): 17–24. PMID 14730506.
  9. Quarles LD (July 2003). “Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues”. Curr. Opin. Nephrol. Hypertens. 12 (4): 349–55. doi:10.1097/01.mnh.0000079682.89474.80. PMID 12815330.
  10. Toka HR, Pollak MR (September 2014). “The role of the calcium-sensing receptor in disorders of abnormal calcium handling and cardiovascular disease”. Curr. Opin. Nephrol. Hypertens. 23 (5): 494–501. doi:10.1097/MNH.0000000000000042. PMID 24992569.
  11. Egbuna OI, Brown EM (March 2008). “Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations”. Best Pract Res Clin Rheumatol. 22 (1): 129–48. doi:10.1016/j.berh.2007.11.006. PMC 2364635. PMID 18328986.
  12. Blaine J, Chonchol M, Levi M (July 2015). “Renal control of calcium, phosphate, and magnesium homeostasis”. Clin J Am Soc Nephrol. 10 (7): 1257–72. doi:10.2215/CJN.09750913. PMC 4491294. PMID 25287933.
  13. Akerström G, Hellman P, Hessman O, Segersten U, Westin G (April 2005). “Parathyroid glands in calcium regulation and human disease”. Ann. N. Y. Acad. Sci. 1040: 53–8. doi:10.1196/annals.1327.005. PMID 15891005.
  14. Carroll R, Matfin G (February 2010). “Endocrine and metabolic emergencies: hypocalcaemia”. Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  15. Carrillo-López N, Fernández-Martín JL, Cannata-Andía JB (2009). “[The role of calcium, calcitriol and their receptors in parathyroid regulation]”. Nefrologia (in Spanish; Castilian). 29 (2): 103–8. doi:10.3265/Nefrologia.2009.29.2.5154.en.full. PMID 19396314.
  16. Wu X, Sonnenberg H (November 1995). “Effect of renal perfusion pressure on excretion of calcium, magnesium, and phosphate in the rat”. Clin. Exp. Hypertens. 17 (8): 1269–85. PMID 8563701.
  17. Mortensen L, Hyldstrup L, Charles P (January 1997). “Effect of vitamin D treatment in hypoparathyroid patients: a study on calcium, phosphate and magnesium homeostasis”. Eur. J. Endocrinol. 136 (1): 52–60. PMID 9037127.
  18. Poole, K; Reeve, J (2005). “Parathyroid hormone — a bone anabolic and catabolic agent”. Current Opinion in Pharmacology. 5 (6): 612–617. doi:10.1016/j.coph.2005.07.004. ISSN 1471-4892.
  19. Cholst IN, Steinberg SF, Tropper PJ, Fox HE, Segre GV, Bilezikian JP (May 1984). “The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects”. N. Engl. J. Med. 310 (19): 1221–5. doi:10.1056/NEJM198405103101904. PMID 6709029.
  20. van den Bergh WM, van de Water JM, Hoff RG, Algra A, Rinkel GJ (2008). “Calcium homeostasis during magnesium treatment in aneurysmal subarachnoid hemorrhage”. Neurocrit Care. 8 (3): 413–7. doi:10.1007/s12028-008-9068-9. PMID 18317951.
  21. Kido Y, Okamura T, Tomikawa M, Yamamoto M, Shiraishi M, Okada Y, Kimura T, Sugimachi K (October 1996). “Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas”. Cancer. 78 (8): 1794–7. PMID 8859194.
  22. Kido Y, Okamura T, Tomikawa M, Yamamoto M, Shiraishi M, Okada Y, Kimura T, Sugimachi K (October 1996). “Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas”. Cancer. 78 (8): 1794–7. PMID 8859194.
  23. Taal, Maarten (2012). Brenner & Rector’s the kidney. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1416061939.
  24. Posillico JT, Wortsman J, Srikanta S, Eisenbarth GS, Mallette LE, Brown EM (October 1986). “Parathyroid cell surface autoantibodies that inhibit parathyroid hormone secretion from dispersed human parathyroid cells”. J. Bone Miner. Res. 1 (5): 475–83. doi:10.1002/jbmr.5650010512. PMID 3332555.
  25. Baron J, Winer KK, Yanovski JA, Cunningham AW, Laue L, Zimmerman D, Cutler GB (May 1996). “Mutations in the Ca(2+)-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism”. Hum. Mol. Genet. 5 (5): 601–6. PMID 8733126.
  26. Brown EM, MacLeod RJ (January 2001). “Extracellular calcium sensing and extracellular calcium signaling”. Physiol. Rev. 81 (1): 239–297. doi:10.1152/physrev.2001.81.1.239. PMID 11152759.
  27. Szalat A, Shpitzen S, Tsur A, Zalmon Koren I, Shilo S, Tripto-Shkolnik L, Durst R, Leitersdorf E, Meiner V (March 2017). “Stepwise CaSR, AP2S1, and GNA11 sequencing in patients with suspected familial hypocalciuric hypercalcemia”. Endocrine. 55 (3): 741–747. doi:10.1007/s12020-017-1241-5. PMID 28176280.
  28. De Luca F, Ray K, Mancilla EE, Fan GF, Winer KK, Gore P, Spiegel AM, Baron J (August 1997). “Sporadic hypoparathyroidism caused by de Novo gain-of-function mutations of the Ca(2+)-sensing receptor”. J. Clin. Endocrinol. Metab. 82 (8): 2710–5. doi:10.1210/jcem.82.8.4166. PMID 9253358.
  29. Hendy GN, Minutti C, Canaff L, Pidasheva S, Yang B, Nouhi Z, Zimmerman D, Wei C, Cole DE (August 2003). “Recurrent familial hypocalcemia due to germline mosaicism for an activating mutation of the calcium-sensing receptor gene”. J. Clin. Endocrinol. Metab. 88 (8): 3674–81. doi:10.1210/jc.2003-030409. PMID 12915654.
  30. Lienhardt A, Garabédian M, Bai M, Sinding C, Zhang Z, Lagarde JP, Boulesteix J, Rigaud M, Brown EM, Kottler ML (April 2000). “A large homozygous or heterozygous in-frame deletion within the calcium-sensing receptor’s carboxylterminal cytoplasmic tail that causes autosomal dominant hypocalcemia”. J. Clin. Endocrinol. Metab. 85 (4): 1695–702. doi:10.1210/jcem.85.4.6570. PMID 10770217.
  31. Løvlie R, Eiken HG, Sørheim JI, Boman H (August 1996). “The Ca(2+)-sensing receptor gene (PCAR1) mutation T151M in isolated autosomal dominant hypoparathyroidism”. Hum. Genet. 98 (2): 129–33. PMID 8698326.
  32. Li D, Opas EE, Tuluc F, Metzger DL, Hou C, Hakonarson H, Levine MA (September 2014). “Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization”. J. Clin. Endocrinol. Metab. 99 (9): E1774–83. doi:10.1210/jc.2014-1029. PMC 4154081. PMID 24823460.
  33. Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T, Rust N, Hobbs MR, Heath H, Thakker RV (June 2013). “Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia”. N. Engl. J. Med. 368 (26): 2476–2486. doi:10.1056/NEJMoa1300253. PMC 3773604. PMID 23802516.

Template:WS Template:WH

Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

Hypocalcemia can be the consequence of multiple disease processes, some of which will be mentioned in the following discussion. Common causes of hypocalcemia include vitamin D insufficiency, hypoparathyroidism, renal disease, pseudohypoparathyroidism, hypomagnesemia, drugs and Fanconi syndrome etc.

Causes

Common Causes

Common causes of hypocalcemia may include:[1]

Less Common Causes

Lessn common causes of hypocalcemia may include:[2]

Causes by Organ System

Cardiovascular No underlying causes
Chemical / poisoning Alcohol abuse
Dermatologic No underlying causes
Drug Side Effect Anticonvulsant therapy, Cabozantinib, Capreomycin sulfate, Chelation therapy, Cinacalcet, Conjugated estrogens/bazedoxifene, Cytarabine, Dactinomycin, Diuretic therapy, Drugs, Edetate disodium, Enemas, Gallium nitrate, Gentamicin, ibandronate, laxatives, Medroxyprogesterone, Nilotinib, Oxcarbazepine, Pamidronic acid, Pentamidine Isethionate, Pramipexole, Sorafenib, Steroid, Thalidomide, Tolbutamide therapy
Ear Nose Throat No underlying causes
Endocrine Absent parathyroid hormone (PTH), Acquired hypoparathyroidism, Adrenocortical hyperplasia, Deficient PTH, Excessive secretion of calcitonin, Familial hypocalcemia, Following thyroidectomy, Hereditary hypoparathyroidism, “Hungry Bone Syndrome” following parathyroidectomy, Hypoparathyroidism, Hypoproteinemia, Medullary carcinoma of the thyroid, Osteitis fibrosa following parathyroidectomy, Osteoporosis, Pseudohypoparathyroidism, Thyroid cancer
Environmental Decreased ultraviolet/sun (vitamin D deficiency), Defective Vitamin D metabolism, Exposure to hydrofluoric acid
Gastroenterologic Acute pancreatitis, Cirrhosis, Decreased dietary intake, Eating disorders, Enemas, laxatives, Intestinal malabsorption, Malabsorption, Maldigestion, Pancreatitis, Rickets, Short bowel syndrome, Vitamin-D dependent rickets, type I
Genetic DiGeorge’s Syndrome, Familial hypocalcemia
Hematologic Hypoalbuminemia (pseudohypocalcemia), Transfusion of citrated blood, Tumor lysis syndrome
Iatrogenic No underlying causes
Infectious Disease Sepsis, Septic shock
Musculoskeletal / Ortho Enhanced bone formation, Excessive secretion of calcitonin, Neonatal tetany, Osteitis fibrosa following parathyroidectomy, Osteoporosis, Rickets, Vitamin-D dependent rickets, type I
Neurologic No underlying causes
Nutritional / Metabolic Absent active vitamin D, Decreased dietary intake, Hyperphosphatemia, Intestinal malabsorption, Intravenous phosphate administration, Magnesium depletion, Rickets, Vitamin D deficiency
Obstetric/Gynecologic Breast cancer
Oncologic Breast cancer, Bronchial cancer, Medullary carcinoma of the thyroid, Osteoblastic metastases, Thyroid cancer, Tumor lysis syndrome
Opthalmologic No underlying causes
Overdose / Toxicity Magnesium over supplementation, Prolonged use of medications/laxatives containing magnesium
Psychiatric Eating disorders
Pulmonary Bronchial cancer, Hyperventilation
Renal / Electrolyte Acute renal failure, Alkalosis, Chronic renal failure, Hypomagnesemia, Hypoproteinemia, Increased diuresis with physiologic saline solution, Intravenous phosphate administration, Kidney diseases with reduced formation of activated vitamin D, Magnesium depletion, Magnesium over supplementation, Nephrotic syndrome, Renal failure, Rhabdomyolysis, Severe acute hyperphosphatemia
Rheum / Immune / Allergy DiGeorge’s Syndrome, Osteitis fibrosa following parathyroidectomy, Polyglandular autoimmune syndrome
Sexual No underlying causes
Trauma Burns
Urologic Acute renal failure, Chronic renal failure, Hypoproteinemia, Renal failure
Miscellaneous Postoperative, Transfusion of citrated blood

Causes in Alphabetical Order

The unnamed parameter 2= is no longer supported. Please see the documentation for {{columns-list}}.
3

References

  1. Fong J, Khan A (February 2012). “Hypocalcemia: updates in diagnosis and management for primary care”. Can Fam Physician. 58 (2): 158–62. PMC 3279267. PMID 22439169.
  2. Fong J, Khan A (February 2012). “Hypocalcemia: updates in diagnosis and management for primary care”. Can Fam Physician. 58 (2): 158–62. PMC 3279267. PMID 22439169.

Template:WS Template:WH

Differentiating Hypocalcemia from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

Hypocalcemia must be differentiated from tetanus, neuroleptic malignant syndrome, viral meningitis, Stiff man syndrome, strychnine poisoning and Parkinson’s disease.

Differential Diagnosis

Hypocalcemia must be differentiated from other diseases causing stiffness and fever. The differentials include the following:

Differential Diagnosis of Tetanus
Disease Diagnosis Treatment
Symptoms Signs Laboratory Findings
Tetanus[1][2]
  • Not significant
Neuroleptic Malignant Syndrome [3][4]
Viral Meningitis[5][6][7]
Stiff man syndrome
  • Marked rigidity
  • Spasms
    • Intermittent
    • Painful
    • Absent during sleep
Drug induced (Tardive dyskinesia)[8][9][10]
  • History of intake of the offending drug for at least one month
  • Eye deviation
  • Head and neck jerky movements
  • No tonic contraction of the muscles between the spasms
Strychnine poisoning[11][12][13][14]
  • Hx of up to date tetanus immunizations
  • History of intentional or accidental intake
    • Strychnos nux vomica seeds
    • Rodenticide
  • Hypervigilance
  • Anxiety
  • Mydriasis
  • Hypereflexia
  • Clonus
  • Facial and neck stiffness
  • Blood assay
  • Tissue assay
  • Urine assay
  • Initial stabilization
  • High dose Benzodiazepines
  • Intubation and airway securing
Hypocalcaemia[15][16]
Parkinson’s disease[17][18]
  • Clinical diagnosis
  • Improvement with dopaminergic therapy confirms diagnosis

References

  1. Woldeamanuel YW, Andemeskel AT, Kyei K, Woldeamanuel MW, Woldeamanuel W (2016). “Case fatality of adult tetanus in Africa: Systematic review and meta-analysis”. J Neurol Sci. 368: 292–9. doi:10.1016/j.jns.2016.07.025. PMID 27538652.
  2. Thwaites CL, Loan HT (2015). “Eradication of tetanus”. Br Med Bull. 116: 69–77. doi:10.1093/bmb/ldv044. PMC 4674006. PMID 26598719.
  3. Hosseini S, Elyasi F (2017). “Olanzapine-Induced Neuroleptic Malignant Syndrome”. Iran J Med Sci. 42 (3): 306–309. PMC 5429500. PMID 28533580.
  4. Leenhardt F, Perier D, Pinzani V, Giraud I, Villiet M, Castet-Nicolas A; et al. (2017). “Pharmacist intervention to detect drug adverse events on admission to the emergency department: Two case reports of neuroleptic malignant syndrome”. J Clin Pharm Ther. doi:10.1111/jcpt.12531. PMID 28488314.
  5. Chow E, Troy SB (2014). “The differential diagnosis of hypoglycorrhachia in adult patients”. Am J Med Sci. 348 (3): 186–90. doi:10.1097/MAJ.0000000000000217. PMC 4065645. PMID 24326618.
  6. Leen WG, Willemsen MA, Wevers RA, Verbeek MM (2012). “Cerebrospinal fluid glucose and lactate: age-specific reference values and implications for clinical practice”. PLoS One. 7 (8): e42745. doi:10.1371/journal.pone.0042745. PMC 3412827. PMID 22880096.
  7. Tyler KL (2004). “Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including Mollaret’s”. Herpes. 11 Suppl 2: 57A–64A. PMID 15319091.
  8. Deng ZD, Li DY, Zhang CC, Pan YX, Zhang J, Jin H; et al. (2017). “Long-term follow-up of bilateral subthalamic deep brain stimulation for refractory tardive dystonia”. Parkinsonism Relat Disord. doi:10.1016/j.parkreldis.2017.05.010. PMID 28552340.
  9. “Valbenazine (Ingrezza) for tardive dyskinesia”. Med Lett Drugs Ther. 59 (1521): 83–84. 2017. PMID 28520698.
  10. Voelker R (2017). “Tardive Dyskinesia Drug Approved”. JAMA. 317 (19): 1942. doi:10.1001/jama.2017.5537. PMID 28510661.
  11. Charlotte Duverneuil, Geoffroy Lorin de la Grandmaison, Philippe de Mazancourt & Jean-Claude Alvarez (2004). “Liquid chromatography/photodiode array detection for determination of strychnine in blood: a fatal case report”. Forensic science international. 141 (1): 17–21. doi:10.1016/j.forsciint.2003.12.010. PMID 15066709. Unknown parameter |month= ignored (help)
  12. B. A. Smith (1990). “Strychnine poisoning”. The Journal of emergency medicine. 8 (3): 321–325. PMID 2197324. Unknown parameter |month= ignored (help)
  13. B. J. Maron, J. R. Krupp & B. Tune (1971). “Strychnine poisoning successfully treated with diazepam”. The Journal of pediatrics. 78 (4): 697–699. PMID 5547830. Unknown parameter |month= ignored (help)
  14. B. Oberpaur, A. Donoso, C. Claveria, C. Valverde & M. Azocar (1999). “Strychnine poisoning: an uncommon intoxication in children”. Pediatric emergency care. 15 (4): 264–265. PMID 10460082. Unknown parameter |month= ignored (help)
  15. Chhabra P, Rana SS, Sharma V, Sharma R, Bhasin DK (2016). “Hypocalcemic tetany: a simple bedside marker of poor outcome in acute pancreatitis”. Ann Gastroenterol. 29 (2): 214–20. doi:10.20524/aog.2016.0015. PMC 4805743. PMID 27065735.
  16. Desai M, Kolla PK, Reddy PL (2013). “Calcium unresponsive hypocalcemic tetany: gitelman syndrome with hypocalcemia”. Case Rep Med. 2013: 197374. doi:10.1155/2013/197374. PMC 3792521. PMID 24171002.
  17. Olanow CW, Watts RL, Koller WC (2001). “An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines”. Neurology. 56 (11 Suppl 5): S1–S88. PMID 11402154.
  18. Connolly BS, Lang AE (2014). “Pharmacological treatment of Parkinson disease: a review”. JAMA. 311 (16): 1670–83. doi:10.1001/jama.2014.3654. PMID 24756517.

Template:WS Template:WH

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

Hypocalcemia is defined as having a low calcium concentration in blood.The normal range of serum calcium lies between 8.8–10.7 mg/dl or 4.3–5.2 mEq/l. In the past 20 years quantification of serum and ionized calcium and PTH concentrations has helped in easier diagnosis. It is difficult to quantify the incidence of ionized hypocalcemia.

Epidemiology and Demographics

Incidence

Mortality rate

  • The mortality rate of hypocalcemia is approximately 44% in acutely ill patients in a medical intensive care setting.[7][8]
  • Hypocalcemia has been reported in critically ill patients, most commonly in association with sepsis syndrome.[9]

References

  1. Zivin JR, Gooley T, Zager RA, Ryan MJ (April 2001). “Hypocalcemia: a pervasive metabolic abnormality in the critically ill”. Am. J. Kidney Dis. 37 (4): 689–98. PMID 11273867.
  2. Chernow B, Zaloga G, McFadden E, Clapper M, Kotler M, Barton M, Rainey TG (December 1982). “Hypocalcemia in critically ill patients”. Crit. Care Med. 10 (12): 848–51. PMID 7140332.
  3. Noureldine SI, Genther DJ, Lopez M, Agrawal N, Tufano RP (November 2014). “Early predictors of hypocalcemia after total thyroidectomy: an analysis of 304 patients using a short-stay monitoring protocol”. JAMA Otolaryngol Head Neck Surg. 140 (11): 1006–13. doi:10.1001/jamaoto.2014.2435. PMC 4316663. PMID 25321339.
  4. Baldassarre RL, Chang DC, Brumund KT, Bouvet M (2012). “Predictors of hypocalcemia after thyroidectomy: results from the nationwide inpatient sample”. ISRN Surg. 2012: 838614. doi:10.5402/2012/838614. PMC 3403163. PMID 22844618.
  5. Edafe O, Prasad P, Harrison BJ, Balasubramanian SP (April 2014). “Incidence and predictors of post-thyroidectomy hypocalcaemia in a tertiary endocrine surgical unit”. Ann R Coll Surg Engl. 96 (3): 219–23. doi:10.1308/003588414X13814021679753. PMC 4474053. PMID 24780788.
  6. Noureldine SI, Genther DJ, Lopez M, Agrawal N, Tufano RP (November 2014). “Early predictors of hypocalcemia after total thyroidectomy: an analysis of 304 patients using a short-stay monitoring protocol”. JAMA Otolaryngol Head Neck Surg. 140 (11): 1006–13. doi:10.1001/jamaoto.2014.2435. PMC 4316663. PMID 25321339.
  7. Desai TK, Carlson RW, Geheb MA (February 1988). “Prevalence and clinical implications of hypocalcemia in acutely ill patients in a medical intensive care setting”. Am. J. Med. 84 (2): 209–14. PMID 3407650.
  8. Chernow B, Zaloga G, McFadden E, Clapper M, Kotler M, Barton M, Rainey TG (December 1982). “Hypocalcemia in critically ill patients”. Crit. Care Med. 10 (12): 848–51. PMID 7140332.
  9. Zivin JR, Gooley T, Zager RA, Ryan MJ (April 2001). “Hypocalcemia: a pervasive metabolic abnormality in the critically ill”. Am. J. Kidney Dis. 37 (4): 689–98. PMID 11273867.

Template:WS Template:WH

Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

The most common risk factor of hypocalcemia is vitamin D deficiency. Other common causes of hypocalcemia include low intake of magnesium, newborn babies, parathyroid hormone (PTH), hyperphosphatemia and chronic kidney disease.

Risk Factors

Common Risk Factors

Less Common Risk Factors

References

  1. Carroll R, Matfin G (February 2010). “Endocrine and metabolic emergencies: hypocalcaemia”. Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  2. Riccardi D, Brown EM (March 2010). “Physiology and pathophysiology of the calcium-sensing receptor in the kidney”. Am. J. Physiol. Renal Physiol. 298 (3): F485–99. doi:10.1152/ajprenal.00608.2009. PMC 2838589. PMID 19923405.
  3. Lee S, Mannstadt M, Guo J, Kim SM, Yi HS, Khatri A, Dean T, Okazaki M, Gardella TJ, Jüppner H (October 2015). “A Homozygous [Cys25]PTH(1-84) Mutation That Impairs PTH/PTHrP Receptor Activation Defines a Novel Form of Hypoparathyroidism”. J. Bone Miner. Res. 30 (10): 1803–13. doi:10.1002/jbmr.2532. PMC 4580526. PMID 25891861.
  4. Dickerson RN, Alexander KH, Minard G, Croce MA, Brown RO (2004). “Accuracy of methods to estimate ionized and “corrected” serum calcium concentrations in critically ill multiple trauma patients receiving specialized nutrition support”. JPEN J Parenter Enteral Nutr. 28 (3): 133–41. doi:10.1177/0148607104028003133. PMID 15141404.
  5. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS (June 2008). “Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review”. J. Clin. Oncol. 26 (16): 2767–78. doi:10.1200/JCO.2007.15.0177. PMID 18509186.
  6. Murray RM, Grill V, Crinis N, Ho PW, Davison J, Pitt P (September 2001). “Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer”. J. Clin. Endocrinol. Metab. 86 (9): 4133–8. doi:10.1210/jcem.86.9.7864. PMID 11549639.
  7. Smallridge RC, Wray HL, Schaaf M (July 1981). “Hypocalcemia with osteoblastic metastases in patient with prostate carcinoma. A cause of secondary hyperparathyroidism”. Am. J. Med. 71 (1): 184–8. PMID 7246580.

Template:WS Template:WH

Screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

There is insufficient evidence to recommend routine screening for hypocalcemia.

Screening

Hypocalcemia can occur either acutely or chronically in hospitalized patients and outpatients, there is insufficient evidence to recommend routine screening for hypocalcemia.

References

Template:WS Template:WH

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

The clinical features of hypocalcemia may vary widely, and range from asymptomatic to life-threatening complications.The main factors that influence serum calcium levels are parathyroid hormone (PTH), vitamin D, ionized calcium, and phosphate. Hypocalcemia is commonly encountered in patients who are hospitalized. Under treatment or improper treatment of hypocalcemic emergencies can lead to significant morbidity. Death is rare but has been reported in hypocalcemia patients.

Natural History

Complications

Prognosis

References

  1. Kelly A, Levine MA (2013). “Hypocalcemia in the critically ill patient”. J Intensive Care Med. 28 (3): 166–77. doi:10.1177/0885066611411543. PMID 21841146.
  2. Carroll R, Matfin G (February 2010). “Endocrine and metabolic emergencies: hypocalcaemia”. Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  3. Lee S, Mannstadt M, Guo J, Kim SM, Yi HS, Khatri A, Dean T, Okazaki M, Gardella TJ, Jüppner H (October 2015). “A Homozygous [Cys25]PTH(1-84) Mutation That Impairs PTH/PTHrP Receptor Activation Defines a Novel Form of Hypoparathyroidism”. J. Bone Miner. Res. 30 (10): 1803–13. doi:10.1002/jbmr.2532. PMC 4580526. PMID 25891861.
  4. Mizunashi K, Furukawa Y, Abe K, Yoshinaga K (December 1993). “The relationship between serum intact parathyroid hormone and calcium in idiopathic hypoparathyroidism”. Calcif. Tissue Int. 53 (6): 378–83. PMID 8293350.
  5. Carroll R, Matfin G (February 2010). “Endocrine and metabolic emergencies: hypocalcaemia”. Ther Adv Endocrinol Metab. 1 (1): 29–33. doi:10.1177/2042018810366494. PMC 3474611. PMID 23148147.
  6. Garabédian M (June 1998). “[Hypocalcemia]”. Rev Prat (in French). 48 (11): 1201–6. PMID 9781172.
  7. Reber PM, Heath H (January 1995). “Hypocalcemic emergencies”. Med. Clin. North Am. 79 (1): 93–106. PMID 7808098.
  8. Macefield G, Burke D (February 1991). “Paraesthesiae and tetany induced by voluntary hyperventilation. Increased excitability of human cutaneous and motor axons”. Brain. 114 ( Pt 1B): 527–40. PMID 2004255.
  9. Thurlow JS, Yuan CM (April 2016). “Dialysate-induced hypocalcemia presenting as acute intradialytic hypotension: A case report, safety review, and recommendations”. Hemodial Int. 20 (2): E8–E11. doi:10.1111/hdi.12386. PMID 26923551.
  10. Levine SN, Rheams CN (June 1985). “Hypocalcemic heart failure”. Am. J. Med. 78 (6 Pt 1): 1033–5. PMID 4014262.
  11. Wong CK, Lau CP, Cheng CH, Leung WH, Freedman B (August 1990). “Hypocalcemic myocardial dysfunction: short- and long-term improvement with calcium replacement”. Am. Heart J. 120 (2): 381–6. PMID 2382615.
  12. Kudoh C, Tanaka S, Marusaki S, Takahashi N, Miyazaki Y, Yoshioka N, Hayashi M, Shimamoto K, Kikuchi K, Iimura O (April 1992). “Hypocalcemic cardiomyopathy in a patient with idiopathic hypoparathyroidism”. Intern. Med. 31 (4): 561–8. PMID 1633370.
  13. Denlinger JK, Nahrwold ML (1976). “Cardiac failure associated with hypocalcemia”. Anesth. Analg. 55 (1): 34–6. PMID 942827.
  14. Brunelli SM, Sibbel S, Do TP, Cooper K, Bradbury BD (October 2015). “Facility Dialysate Calcium Practices and Clinical Outcomes Among Patients Receiving Hemodialysis: A Retrospective Observational Study”. Am. J. Kidney Dis. 66 (4): 655–65. doi:10.1053/j.ajkd.2015.03.038. PMID 26015274.
  15. Gupta MM (October 1989). “Medical emergencies associated with disorders of calcium homeostasis”. J Assoc Physicians India. 37 (10): 629–31. PMID 2632508.
  16. Manuel VR, Martin SA, Juan SR, Fernando MA, Frerk M, Thomas K, Christian H (2015). “Hypocalcemia as a prognostic factor in mortality and morbidity in moderate and severe traumatic brain injury”. Asian J Neurosurg. 10 (3): 190–4. doi:10.4103/1793-5482.161171. PMC 4553730. PMID 26396605.
  17. Vinas-Rios JM, Sanchez-Aguilar M, Sanchez-Rodriguez JJ, Gonzalez-Aguirre D, Heinen C, Meyer F, Kretschmer T (February 2014). “Hypocalcaemia as a prognostic factor of early mortality in moderate and severe traumatic brain injury”. Neurol. Res. 36 (2): 102–6. doi:10.1179/1743132813Y.0000000272. PMID 24139087.

Template:WS Template:WH

Diagnosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case Studies

Case #1

Related Chapters
References

References


Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH